Sanofi has opened a new UK Headquarters, based at Thames Valley Park in Reading, Berkshire.
The company welcomed Matt Hancock, secretary of state for health and social care, to open the “state of the art” facility, along side Paul Hudson, chief executive officer of Sanofi and Hugo Fry, UK’s managing director.
The new 70,000 square ft. office facility marks a £37 million investment to Reading and will be the new base for 500 of the 1,200 employees in the UK.
“We are delighted to unveil our new headquarters and it has been an honour to welcome the Rt Hon Matt Hancock, secretary of state for health and social care, to today’s event,” says Hugo Fry, managing director at Sanofi in the UK.
He continued, “Thames Valley Park is well located and connected, but also home to global technology leaders and one of the best places for life sciences in the world. Just as delivering the best outcomes for the one million UK patients we support every month is important to us, we paid particular attention to designing a space that promotes the health and wellbeing of our employees.”
The company revealed that it is actively seeking to recruit at least 50 new roles in the coming months, in addition to ten graduate students via its new Aspiring Leaders programme.
By Anna Smith
Source: Pharma Times
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”